Join Windtree Therapeutics for a virtual investor day featuring the new positive topline results of the Phase 2b SEISMiC Extension Study of istaroxime in early cardiogenic shock, istaroxime cardiogenic shock opportunity and the Windtree’s strategy going forward, including planned near-term milestones
Craig Fraser, Eric Curtis, Steve Simonson
https://lifescievents.com/event/windtreetx/
